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Abstract
The majority of high-risk neuroblastomas can be divided into three distinct molecular subgroups defined by the
presence of MYCN amplification, upstream TERT rearrangements or alternative lengthening of telomeres (ALT). The
common defining feature of all three subgroups is altered telomere maintenance; MYCN amplification and
upstream TERT rearrangements drive high levels of telomerase expression whereas ALT is a telomerase independent
telomere maintenance mechanism. As all three telomere maintenance mechanisms are independently associated
with poor outcomes, the development of strategies to selectively target either telomerase expressing or ALT cells
holds great promise as a therapeutic approach that is applicable to the majority of children with aggressive disease.
Here we summarise the biology of telomere maintenance and the molecular drivers of aggressive neuroblastoma
before describing the most promising therapeutic strategies to target both telomerase expressing and ALT cancers.
For telomerase-expressing neuroblastoma the most promising targeted agent to date is 6-thio-2′-deoxyguanosine,
however clinical development of this agent is required. In osteosarcoma cell lines with ALT, selective sensitivity to
ATR inhibition has been reported. However, we present data showing that in fact ALT neuroblastoma cells are more
resistant to the clinical ATR inhibitor AZD6738 compared to other neuroblastoma subtypes. More recently a number
of additional candidate compounds have been shown to show selectivity for ALT cancers, such as Tetra-Pt (bpy), a
compound targeting the telomeric G-quadruplex and pifithrin-α, a putative p53 inhibitor. Further pre-clinical
evaluation of these compounds in neuroblastoma models is warranted.
In summary, telomere maintenance targeting strategies offer a significant opportunity to develop effective new
therapies, applicable to a large proportion of children with high-risk neuroblastoma. In parallel to clinical
development, more pre-clinical research specifically for neuroblastoma is urgently needed, if we are to improve
survival for this common poor outcome tumour of childhood.
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Background
Neuroblastoma is a common childhood malignancy aris-
ing from the sympathetic nervous system. It most com-
monly arises from the adrenal gland and presents with
an abdominal mass, but has a heterogeneous clinical
phenotype. Children aged less than 18 months often
present with widespread metastases to the skin, liver and
bone marrow (stage MS disease) [1], however this can
spontaneously resolve without treatment. Conversely,
distant metastatic spread in children aged greater than
18months (stage M disease) is associated with an
aggressive clinical phenotype and poor survival [1, 2].
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Children aged > 18 months with stage M disease and/
or amplification of the MYCN oncogene are classified as
having clinical high-risk disease. High-risk neuroblast-
oma remains a major therapeutic challenge with survival
rates of < 50% despite intensification of therapy [2, 3].
However, until recently, in the absence of MYCN ampli-
fication, the molecular drivers of aggressive disease were
unknown.
In 2015 it was reported that aggressive neuroblast-
oma can be divided into 3 almost mutually exclusive
subgroups with either MYCN amplification, rearrange-
ments upstream to the telomerase reverse transcript-
ase (TERT) gene or alternative lengthening of
telomeres (ALT) [4, 5]. Each subgroup is associated
with the activation of a telomere maintenance mech-
anism (TMM) and poor outcomes. Conversely, it is
thought that the absence of a TMM is associated with
spontaneous regression and excellent survival [6].
Here we summarise TMMs in cancer, specifically fo-
cusing on the molecular alterations driving telomere
maintenance in neuroblastoma, before describing poten-
tial novel therapeutic strategies to directly target TMMs
for children with neuroblastoma.
Biology of telomere maintenance
Telomeres are regions of repetitive nucleotide sequences
(TTAGGG) located at the ends of chromosomes that
protect chromosomes from DNA damage, unnecessary
DNA repair and fusion with other chromosomes. In nor-
mal dividing cells, with each cell replication telomeres
gradually shorten, until a critical level is reached, the
Hayflick limit, after which cells undergo senescence [7].
This gradual shortening of telomeres associated with cel-
lular aging is believed to be a protective mechanism
against uncontrolled growth, preventing cancer develop-
ment in humans and other mammals [8]. In keeping
with this, the activation of a TMM to prevent the short-
ening of telomeres is necessary for the continued
sustained proliferation of cancer cells and hence a hall-
mark of cancer [9].
Telomerase, a functional ribonucleoprotein enzyme
complex, maintains telomere length by adding telomeric
DNA repeats at the 3′ ends of linear chromosomes. It is
a reverse transcriptase that consists of a catalytic protein
subunit TERT, and an essential RNA component known
as human telomerase RNA (hTR), encoded by hTERC.
hTR acts as a template for the synthesis of telomere
DNA and is involved in the catalysis, localisation, and
assembly of the telomerase holoenzyme [10, 11]. Tel-
omerase is widely expressed in human embryos between
16 and 20 weeks gestation, however by the early neonatal
period telomerase activity can no longer be detected in
most somatic tissues [12]. In contrast, the majority of
cancers overexpress telomerase: in a systematic analysis
of 31 tumour types, over-expression of TERT was identi-
fied in 73% of all cancers [13]. This was most commonly
associated with genetic alterations in either the TERT
gene/promoter or TERT promoter methylation.
ALT is defined as maintenance of telomeres in the
absence of telomerase activity [14]. It can be detected in
10–15% cancers overall but is particularly prevalent in
tumours of mesenchymal origin [14, 15]. There is a
strong association between ALT and loss of function
(LoF) genetic alterations in ATRX (Alpha Thalassemia
mental Retardation-X linked) in multiple malignancies,
including neuroblastoma [13, 16–18].
A number of different non-canonical homologous re-
combination (HR) based mechanisms have been proposed
to play a role in ALT telomere maintenance [19–22]. Fur-
thermore, a number of studies have focused on the under-
lying basis for the relationship between ATRX LoF and
the development of the non-canonical HR mechanisms
implicated in ALT (summarised in Fig. 1). Firstly an estab-
lished role of ATRX is the maintenance of genomic
stability via the deposition of H3.3 into telomeric regions
[24, 25]. In the absence of ATRX, G4 quadruplex struc-
tures may occur in guanine rich regions of DNA such as
Fig. 1 Mechanisms underlying the relationship between ATRX loss of function and ALT. Diagram of (a) a normal and (b) an ALT telomere. In
normal cells ATRX and H3.3 co-localise with telomeric DNA, within PML bodies [23]. Following ATRX LoF, MRN complexes co-localise with PML
bodies and a failure of telomeric H3.3 deposition results in G-quadruplex formation, facilitating non-canonical homologous recombination
mechansims. Additionally, in the absence of functional ATRX, TERRA binds to telomeric DNA, facilitaing the formation of DNA-RNA hybrids known
as R-loops which also promote homologous recombination repair
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telomeres, resulting in stalling of replication forks, which
provides a substrate for HR [26, 27]. Secondly, in the
absence of ATRX, the MRN (Mre11-RAD50-Nbs1) com-
plex is redistributed to ALT associated PML body sites
where it is thought to also facilitate HR mechanisms [26].
Finally, it has been shown that the long non-coding RNA
TElomeric Repeat-containing RNA (TERRA) is function-
ally antagonistic with ATRX [28], and therefore in the ab-
sence of ATRX, TERRA can form DNA-RNA hybrids
known as R loops, that promote homology directed repair
of telomeres [29]. Further confirming the role of ATRX as
an ALT repressor, ATRX knockdown has been shown to
induce ALT activity in cells of mesenchymal origin [30].
However, ATRX depletion does not promote ALT activity
in all cell types [31, 32] suggesting that ATRX LoF alone
is not sufficient to induce ALT and that additional, as yet
unidentified mechanisms are also needed. Reinforcing the
notion that ALT arises as a result a combination of ATRX
loss and other factors, it has recently been shown that dur-
ing the immortalisation process, ATRX loss results in a
progressive chromatin de-compaction and a gradual in-
duction of telomere replication dysfunction which triggers
an adaptive response eventually resulting in ALT activa-
tion [33]. Furthermore the authors show that the telomere
dysfunction induced by ATRX loss cannot be overcome
by endogenous telomerase activity.
Genetic alterations in the histone chaperone and
ATRX binding partner DAXX (death domain associated
protein) have also been shown to result in ALT due to a
failure to localise ATRX to PML bodies [34]. In addition
genetic alterations in tumour protein 53 (TP53) and ret-
inoblastoma 1 (RB1) have also been associated with ALT
[13] however the mechanistic basis for these associations
is currently unknown.
Biomarkers of TMM
In large-scale studies telomerase expression data is often
used as a surrogate biomarker for telomerase activity
[13], however quantification of telomerase activity by
standardised assays based on the telomere repeat ampli-
fication (TRAP) protocol is also feasible in clinical trial
settings both as a predictive biomarker in tumour tissue
and as pharmacodynamic biomarker in peripheral blood
mononuclear cells [35].
The identification of robust biomarkers of ALT has
proved more challenging. The gold standard assay for
ALT is to confirm the maintenance of telomeres, in the
absence of telomerase activity through successive popu-
lation doublings. However, this is only practical in cell
lines, non quantitative, and requires long-term cell cul-
ture [14]. Although telomere length and telomere het-
erogeneity are often used as biomarkers of ALT the lack
of specificity of these assays for ALT is becoming in-
creasingly apparent [14, 36, 37].
PML bodies are ubiquitous throughout the genome
and responsible for diverse functions including DNA re-
pair. In ALT cancer cells PML bodies specifically co-
localise to telomeric DNA, and are thought to facilitate
HR [14, 26]. ALT associated PML bodies are now a
well-established biomarker of ALT activity and have the
advantage that they can be visualised in formalin fixed
paraffin embedded (FFPE) material [14, 38].
ALT cells are also characterised by the presence of c-
circles: single stranded, telomeric circular DNA strands
which are thought to provide a template for ALT telo-
mere synthesis [14]. The c-circle assay is a rolling circle
PCR amplification assay, based on the self-priming na-
ture of c-circles. The c-circle assay requires fresh-frozen
tissue but is advantageous as c-circles are quantifiable,
specific for ALT and c-circle levels can be used to evalu-
ate response to ALT targeted agents [39, 40].
Telomeres and telomere lengthening in neuroblastoma
Amplification of the MYCN oncogene is found in almost
40% of clinical high-risk neuroblastomas [4, 41], and is
associated with up-regulation of TERT expression and
telomere dysfunction [4, 42]. In an additional 23–31% of
high-risk neuroblastomas, TERT is activated through
chromosomal rearrangements involving 5p15.33, prox-
imal to the TERT gene, which induces transcriptional
up-regulation of TERT by juxtaposing the TERT coding
sequence with strong enhancer elements [4, 5]. The
third distinct sub-group, accounting for 24% of high-risk
neuroblastoma cases are those with ALT [36]. Approxi-
mately half of ALT neuroblastomas are associated with
somatic alterations in ATRX [4, 5, 36]. In neuroblastoma,
genetic alterations in ATRX are associated with a distinct
clinical phenotype including older age at diagnosis and a
chronic progressive disease course [43].
Neuroblastoma harbouring a TMM is associated with
a poor prognosis regardless of clinical stage [4, 5, 44–
46]. More recently it has been shown that in the pres-
ence of a TMM a concurrent mutation in a TP53 or
RAS pathway associated gene is associated with an even
worse prognosis [6]. Conversely, neuroblastoma with
TP53 or RAS pathway mutations (including canonical
ALK mutations) in the absence of a concurrent TMM
are not associated with worse survival and can spontan-
eously regress [6]. This molecular risk stratification of
neuroblastoma, as described by Ackermann et al. [6] is
summarised in Fig. 2.
Although the somatic alterations driving TMM’s in
the majority of neuroblastoma are well defined, high tel-
omerase expression can occur in the absence of either a
TERT translocation or MYCN amplification [6]. Also in
the absence of an ATRX alteration the underlying drivers
of ALT neuroblastoma are currently unknown, and som-
atic alterations in other genes, known to be associated
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with ALT in other malignancies are rarely found in
neuroblastoma [47]. Numerous additional mechansims
for telomere maintenance in neuroblastoma have been
suggested. A study has identified interstitial telomeric se-
quences at sites of unbalanced translocations in neuro-
blastoma cell lines and postulated that these may
contribute to a defective telomere maintenance pathway
[48]. Another possibility is that genetic predisposition
may contribute to the development of TMMs. In keep-
ing with this, six common single nucleotide polymor-
phisms known to be associated with telomere
lengthening have been found to be associated with
an increased risk of neuroblastoma [49]. In keeping
with the hypothesis that additional underlying pre-
disposing factors may contribute to TMMs, a sub-
stantial increase in telomeric DNA damage and
active telomere trimming has been described consist-
ently across all high-risk neuroblastomas, regardless
of telomerase or ALT status [50].
In summary, data is accumulating to support the hy-
pothesis that TMMs are the common defining molecular
feature of aggressive disease in the majority of children
with clinical high-risk neuroblastoma. Therefore, both
telomerase and ALT represent attractive targets for the
development of novel therapeutic strategies with the po-
tential to benefit a significant proportion of high-risk
neuroblastoma patients. Here, we review the current
pre-clinical and clinical research focused on targeting
telomere maintenance with a specific focus on the po-
tential relevance to patients with neuroblastoma.
Drugs targeting telomerase activity
Imetelstat (GRN163L) is a competitive telomerase in-
hibitor with a complementary structure to the template
region of the RNA component of telomerase that binds
to and blocks the active site of the enzyme [51]. Con-
firmation of target inhibition and pre-clinical efficacy of
imetelstat has been demonstrated in multiple cancer
subtypes [52–54].
A phase I trial of imetelstat in 20 children with refrac-
tory or recurrent solid tumours demonstrated telomer-
ase inhibition, which was sustained through to day 8 of
cycle 1 of therapy [55]. Two of 16 patients had a partial
response, however no responses were seen in any of the
6 patients with neuroblastoma enrolled on the trial. The
main dose limiting toxicities were neutropenia,
thrombocytopenia, and lymphopenia. A Phase II study
on imetelstat in children with recurrent or refractory
central nervous system malignancies was also associated
with significant haematological toxicity and was discon-
tinued after two children died of intra-tumoral haemor-
rhage [35], thus paediatric development for this
compound has subsequently been discontinued.
BIBR1532 is a potent synthetic, non-nucleoside tel-
omerase inhibitor [56]. However like imetelstat there are
significant concerns regarding toxicity [57], and this
agent has not yet been evaluated in clinical trials.
Sodium metaarsenite (KML001) binds to telomeric
sequences, displacing hTERT from the nucleus into the
cytoplasm [58] and has been shown to be cytotoxic in
neuroblastoma cells in vitro [59]. In a phase I trial in
adults with advanced solid tumours, objective responses
to KML001 and cisplatin were seen in four out of 18 pa-
tients, however this trial was also discontinued due to
toxicity [60].
Telomestatin stabilises G-quadruplexes, which in
turn, inhibits telomerase activity [61]. This compound
has been shown to induce apoptosis in-vitro in telomer-
ase expressing neuroblastoma cell lines [62] but is not
yet in clinical development.
6-thio-2′-deoxyguanosine (6-thio-dG) is a nucleoside
analogue, which in telomerase active cells is recognised
by telomerase and incorporated into telomeres resulting
in telomere dysfunction [63]. Pre-clinical efficacy has
been demonstrated in melanoma, non-small cell lung
cancer and paediatric brain tumour models [64–66]. Al-
though 6-thio-dG has not yet been evaluated in clinical
trials, due to the novel mechanism of action of the com-
pound it is thought to be less toxic than traditional tel-
omerase inhibitors [67]. 6-thio-dG has been shown to be
effective in-vivo in neuroblastoma models with TERT ac-
tivation. However, the response in MYCN amplified
Fig. 2 Molecular risk classification of neuroblastoma [6]. The
presence of a telomere maintenance mechansim is defined as either
MYCN amplification, a TERT rearrangement, telomerase upregulation
or ALT. In neuroblastoma with a TMM the presence of a concurrent
mutation in 1 of 17 defined RAS or TP53 pathway genes defines a
group of patients with particularly poor outcomes. The most
common RAS/TP53 pathway alterations found in neuroblastoma are
activating ALK mutations
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xenografts was mixed, likely reflective of the additional
oncogenic pathways activated by MYCN [47]. This is a
priority compound for further development for neuro-
blastoma (Table 1).
XAV939 is an inhibitor of tankyrase, a positive regula-
tor or telomerase. It has been shown to induce apoptosis
in the telomerase expressing neuroblastoma cell line
SH-SY5Y [70].
Drugs targeting ALT
Ataxia telangiectasia mutated (ATM) inhibitor combination
therapy
It has been reported by Koneru et al. that ALT neuro-
blastoma cell lines are more resistant to topoisomerase
inhibitors and that activation of ATM at ALT telomeres
is associated with chemo-resistance. The ATM inhibitor
AZD0156 was found to be synergistic with temozolo-
mide and irinotecan therapy in both in vitro and in-vivo
models of ALT neuroblastoma [71]. AZD0156 is cur-
rently in phase I trials in adults [72].
Ataxia telangiectasia and Rad3 related (ATR) inhibitor
In 2015 Flynn et al. reported that the presence of ALT
renders cells hypersensitive to ATR inhibition in osteo-
sarcoma models [73]. We have evaluated the clinical
ATR inhibitor AZD6738 [74], in a panel of neuroblast-
oma cell lines and found that in contrast, ALT cell lines
are relatively resistant to ATR inhibition in comparison
to other neuroblastoma cell lines (Fig. 3a-b). This is in
keeping with a subsequent publication which directly
refuted the findings of Flynn et al. and concluded that
differences in ATR inhibitor sensitivity were not related
to ALT [77]. Taken together this data does not currently
support a role of ATR inhibitors as an ALT specific
therapy.
Conversely, we found that MYCN amplified neuroblast-
oma cell lines show a significantly greater in vitro sensitiv-
ity to single agent AZD6738 than non-MYCN amplified
neuroblastoma cell lines (Fig. 3a-c), and a preliminary
dose finding study demonstrated sensitivity to single agent
AZD6738 in the Th-MYCN transgenic mouse model of
MYCN driven neuroblastoma [76] (Fig. 3d-e). This is in
keeping with other cMYC driven tumours where onco-
gene driven replicative stress results in a reliance on ATR
signalling [78, 79]. Also in keeping with this, the SKNAS
neuroblastoma cell line is relatively sensitive to AZD6738
(Fig. 3a) and known to over-express cMYC [80]. InMYCN
amplified neuroblastoma models, ATR has also been pro-
posed to play a role in resolution of transcription/replica-
tion conflicts [81].
Pre-clinical research in other ALT cancers
Recent pre-clinical data focused on the therapeutic tar-
geting of ALT in other cancer subtypes may give import-
ant insight into potential therapeutic vulnerabilities that
can be exploited for ALT neuroblastoma (Table 1):
Tetra-Pt (bpy) is a cisplatin derivative that inhibits telo-
meric homologous recombination by targeting the telo-
meric G-quadruplex and has been shown to inhibit
growth of ALT-cell xenograft tumours in mice [82].
Thus far this agent has not entered clinical trials nor has
been evaluated in neuroblastoma models. CX5461 is an
RNA polymerase I inhibitor which has been shown to
selectively kill ATRX mutant cells due to its effects on
ribosomal RNA transcription. In-vitro sensitivity in ALT
cancer cell lines has been demonstrated [83]. It has also
recently been reported that some ALT cancer cells rely
on p53 and AKT activity to suppress apoptosis. Further-
more the authors go on to show that the p53 inhibitor
pifithrin-α suppresses tumour growth in an ALT xeno-
graft model [84] although others have shown that
pifithrin-α is not a specific inhibitor of p53 [85], calling
into question the underlying mechanism of the demon-
strated pifithrin-α response. This strategy may however
represent a relevant novel therapeutic opportunity for
ALT neuroblastoma, particularly in view of the fact that
the majority of neuroblastoma is TP53 wild type [86].
Finally, preliminary data has shown that ALT cancer cell
Table 1 Compounds shown pre-clinically to target telomere maintenance mechanisms, to be prioritised for evaluation in
neuroblastoma
Drug Target Pre-clinical Data Clinical Trials
6-thio-dG Telomerase Pre-clinical efficacy in TERT activated neuroblastoma models No
Tetra-Pt
(bpy)
ALT In-vitro and in-vivo activity in U2OS ALT osteosarcoma model No
CX-5461 ALT In-vitro activity in U2OS and SAOS2 ALT osteosarcoma cell lines On-going adult phase I clinical trial
(NCT0271997)
Pifithrin-α ALT In-vitro and in-vivo activity in U2OS ALT osteosarcoma model No
Trabectedin ALT In-vitro activity in a panel of ALT cell lines (sarcoma, breast cancer and
melanoma)
-FDA approval for certain soft tissue
sarcomas [68]
-Paediatric sarcoma phase II data [69]
-On-going paediatric clinical trials
(NCT04067115)
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lines are in general more sensitive to trabectedin,
although the mechanism for this is not clear [87].
Tumour heterogeneity, evolution and TMM targeted
therapeutics
In some other paediatric malignancies, ALT (identified
by the presence of ALT associated PML bodies) and
telomerase activation have been shown to co-exist in the
same tumour [88, 89]. In neuroblastoma, intra-tumoural
diversity of telomere length in individual tumours has
been identified using quantitative telomere fluorescence
in-situ hybridisation (FISH) [90], however this is not a
sufficiently sensitive or specific biomarker of ALT activ-
ity [14, 36]. In fact, one study has identified a subset of
neuroblastomas with extremely long telomeres in the
absence of either telomerase activity or ALT (detected
Fig. 3 (a) Representative dose response curve for AZD6738 in a panel of neuroblastoma cell lines (b) Results of 3 independent SF50 experiments
in the panel of neuroblastoma cell lines. Cell lines are grouped and colour coded according to MYCN and ALT [36, 75] status. For SF50 experiments,
cells were seeded into 96-well plates and the following day compound was added to wells in triplicate, across a concentration gradient including
DMSO-only controls. After 5 days cell viability was assessed by Cell Titer Glo® assay. The SF50 was calculated as the drug concentration that inhibits
viability/cell growth by 50% compared with controls, according to non-linear regression analysis, using Graphpad Prism. Statistical comparison of results
is by unpaired t-test (c) MYCN expression by western blot in the panel of cell lines (N-MyC antibody: santa cruz sc-53,993, GAPDH antibody: cell
signaling #2118) (d) Representative images of a Th-MYCN GEMM tumour prior to, and after 7 days treatment with 75 mg/kg AZD6738. (e) Waterfall
plot documenting the relative changes in tumour volume following 7-day treatment with AZD6738 at three different dose levels. Preliminary
studies of AZD6738 were performed in the Th-MYCN model of MYCN amplified neuroblastoma [76]. AZD6738 was supplied by AstraZeneca under a
Material Transfer Agreement. It was diluted in 10% DMSO, 40% propylene glycol and 50% water as per manufacturers instructions. In a dose finding
study three different doses (25 mg/kg, 50 mg/kg and 75 mg/kg) were trialled in 2 mice each for 7 days by oral gavage. Comparison of tumour response
was made between animals receiving vehicle only and AZD6738. For response assessment, magnetic resonance imaging (MRI) of tumours was
performed at day zero and after 7 days of administration of the compound
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by c-circle assay and ALT associated PML bodies) [36].
Further studies have shown that although TERT alter-
ations and MYCN amplification do co-exist in a small
proportion of cases, there is no overlap between the tel-
omerase expressing and ALT positive neuroblastoma
[47]. This is in keeping with a recent publication also
showing that ATRX mutations and MYCN amplification
are synthetically lethal in neuroblastoma [91]. Taken
together, the evidence in neuroblastoma to date is that
the presence of either ALT or telomerase activation is
associated with differing distinct genetic drivers and
occurs in mutually exclusive nature [4, 5].
Although data thus far indicates that subgroups of
neuroblastoma are driven by either telomerase or ALT
activation, it is highly likely that a selective pressure tar-
geting one TMM will support the emergence of an alter-
native mechanism. In multiple other cancer subtypes it
has been shown that long-term telomerase inhibition
results in the emergence of features consistent with ALT
[92–94]. Conversely, with the development of ALT tar-
geted therapeutics it is probable that an up-regulation of
telomerase will be seen. However, encouragingly, follow-
ing ATRX LoF, it appears that ALT is a necessary adap-
tion for cancer cell survival, and that reactivation of
telomerase activity cannot overcome endogenous
telomere dysfunction [33].
Finally although it has been shown that activation of a
TMM is the key determinant of poor outcome in neuro-
blastoma, the key drivers of TMM’s in neuroblastoma;
MYCN amplification and genetic alterations in ATRX
are also associated with distinct patterns of wider tran-
scriptional activation which drive malignant transform-
ation [91, 95, 96]. Furthermore it is known that the co-
occurrence of RAS/TP53 pathway alterations with a
TMM is associated with a particularly dismal outcome
[6] and accordingly, alterations in the RAS and TP53
pathways are enriched at the time of neuroblastoma re-
lapse [97, 98]. Therefore, TMM targeting strategies will
only be beneficial when given in combination with
agents targeting these key pathways and the evaluation
of combination therapies is urgently needed.
Conclusion
Despite evidence that telomere maintenance is a key
driver of aggressive biology in neuroblastoma, clinical
translation of novel therapeutics specifically targeting
telomere maintenance remains extremely challenging.
The only compound to make it into paediatric clinical
trials so far, imetelstat is excessively toxic and pre-
clinical data on other compounds targeting telomerase
activity is extremely limited. The most promising tel-
omerase targeting candidate to date is 6-thio-dG, how-
ever this agent is yet to make it into clinical trials. It
must also be noted that in an aggressive malignancy
such as neuroblastoma, rapid development of resistance
to single-agent targeting of telomerase activation is
highly likely and that combination therapies will be
needed to overcome this. Also, in the case of MYCN
amplified tumours, transcriptional up-regulation of
TERT is only one of many oncogenic programmes up-
regulated in MYCN amplified neuroblastoma cells.
For ALT driven cancers, there is preliminary data sup-
porting specific roles of a handful of targeted therapeutic
approaches but a dearth of robust evidence of pre-
clinical efficacy specifically for neuroblastoma. The com-
bination of ATM inhibition with chemotherapy is
currently the most promising option for ALT neuro-
blastoma, although regimens combining cytotoxic
chemotherapy agents and inhibition of master upstream
regulators of DNA damage repair such as ATM are
likely to be prone to significant toxicities.
Despite these challenges, the development of effective
new strategies for neuroblastoma by either selective tar-
geting of telomerase or ALT offers great potential to
treat the underlying drivers of aggressive disease biology,
and is applicable to the greater proportion of neuroblast-
oma patients. Furthermore, the hypothesis that TMM
targeting strategies may be particularly effective in
neuroblastoma is supported by the fact that significantly
fewer mutations are found in neuroblastoma in compari-
son to adult malignancies, which often arise due to an
accumulation of oncogenic mutations over time [99].
In addition, as recent data identifies an ‘ultra-high risk’
group of neuroblastoma patients with both telomere
maintenance and mutations in RAS and TP53 pathway
genes [6], rational combinations of telomere targeting
agents with other targeted therapeutics must be sought.
As pre-clinical data develops, rationally designed paedi-
atric clinical trials will be required to personalise therapy
to simultaneously target multiple drivers of aggressive
biology in an individual patient.
As our understanding of the molecular drivers of fatal
neuroblastoma has significantly expanded in recent
years, pre-clinical research efforts must now focus on
translating this knowledge into effective, less toxic new
therapies for children with neuroblastoma.
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